Clinical Trial Update: Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study of combining irinotecan liposome with epirubicin in patients with recurrent non-muscle invasive bladder can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Epirubicin (epirubicin)
• Irinotecan liposome (liposomal irinotecan)

Snippet

Sponsor: First Affiliated Hospital of Chongqing Medical University | Conditions: Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 1 | Status: RECRUITING